Literature DB >> 10512365

Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity.

J Kawaki1, K Nagashima, J Tanaka, T Miki, M Miyazaki, T Gonoi, N Mitsuhashi, N Nakajima, T Iwanaga, H Yano, S Seino.   

Abstract

The insulin response to the sulfonylurea glibenclamide was markedly impaired in pancreatic beta-cell line MIN6 cells with chronic glibenclamide treatment (MIN6-Glib). The intracellular calcium concentration increased only slightly in response to glibenclamide in MIN6-Glib. While the properties of the voltage-dependent calcium channels were not altered, the conductance of the K(ATP) channels, the primary target of glibenclamide, was significantly reduced in MIN6-Glib. The ATP-sensitive K+ (K(ATP)) channels in MIN6 cells comprise inwardly rectifying K+ channel member Kir6.2 subunits and sulfonylurea receptor (SUR) 1 subunits. MIN6 cells have both high- and low-affinity binding sites for glibenclamide. The binding affinities at these two sites were unchanged, but the maximum binding capacities at both sites were similarly increased by chronic glibenclamide treatment. Both SUR1 and Kir6.2 mRNA levels were not altered, but SUR1 protein was rather increased in MIN6-Glib. In addition, electron microscopic examination revealed a majority of the SUR1 to be present in a cluster near the plasma membrane in control MIN6, while it tends to be distributed in the cytoplasm in MIN6-Glib. These data suggest that chronic glibenclamide treatment causes the defect in acute glibenclamide-induced insulin secretion by reducing the number of functional K(ATP) channels on the plasma membrane of the beta-cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512365     DOI: 10.2337/diabetes.48.10.2001

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Niflumic acid-sensitive ion channels play an important role in the induction of glucose-stimulated insulin secretion by cyclic AMP in mice.

Authors:  W Fujimoto; T Miki; T Ogura; M Zhang; Y Seino; L S Satin; H Nakaya; S Seino
Journal:  Diabetologia       Date:  2009-03-06       Impact factor: 10.122

2.  Hyperinsulinism induced by targeted suppression of beta cell KATP channels.

Authors:  J C Koster; M S Remedi; T P Flagg; J D Johnson; K P Markova; B A Marshall; C G Nichols
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

3.  Drugs acting on SUR1 to treat CNS ischemia and trauma.

Authors:  J Marc Simard; S Kyoon Woo; Sergei Bhatta; Volodymyr Gerzanich
Journal:  Curr Opin Pharmacol       Date:  2007-11-26       Impact factor: 5.547

4.  Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity.

Authors:  Zhi-Quan Wang; Fu-Er Lu; San-Hua Leng; Xin-Sheng Fang; Guang Chen; Zeng-Si Wang; Li-Ping Dong; Zhong-Qing Yan
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

5.  Acute and long-term effects of nateglinide on insulin secretory pathways.

Authors:  Andrew J Ball; Peter R Flatt; Neville H McClenaghan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

6.  Sulfonylurea receptor 1 mutations that cause opposite insulin secretion defects with chemical chaperone exposure.

Authors:  Emily B Pratt; Fei-Fei Yan; Joel W Gay; Charles A Stanley; Show-Ling Shyng
Journal:  J Biol Chem       Date:  2009-01-16       Impact factor: 5.157

7.  Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.

Authors:  Yutaka Seino; Mads Frederik Rasmussen; Tomoyuki Nishida; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2011-08-02       Impact factor: 4.232

8.  Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.

Authors:  Maria Sara Remedi; Colin G Nichols
Journal:  PLoS Med       Date:  2008-10-28       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.